A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update
Background: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population. Objectives: To describe the main features of the CLEAR study design, incl...
Saved in:
Main Authors: | Kerstin Hellwig, Melinda Magyari, Thomas M. MacDonald, Carolyn E. Cesta, Stig Wergeland, Maarit K. Leinonen, Asher Ornoy, Sandra Vukusic, Alexandra Lauer, Xiaolei Zhou, Alison Kawai, Rachel Weinrib, Alejandro Arana, Tahani Boumenna |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864241310996 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Multiple Sclerosis with Cladribine Tablets: Literature Review and the Guidance of the Lithuanian Association of Neurologists
by: R. Kizlaitienė, et al.
Published: (2024-03-01) -
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
by: Heinz Wiendl, et al.
Published: (2025-02-01) -
Intrinsic Apoptosis Pathway in Fallopian Tube Epithelial Cells Induced by Cladribine
by: Ewelina Wawryk-Gawda, et al.
Published: (2014-01-01) -
Selective Serotonin Reuptake Inhibitors in Human Pregnancy: To Treat or Not to Treat?
by: Orna Diav-Citrin, et al.
Published: (2012-01-01) -
The Importance of Olfaction for Mixed Paternity in Birds
by: Charlotta Kvarnemo, et al.
Published: (2025-01-01)